Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL2-BZAG Trial in Relapsed/Refractory CLL
NCT04515238Phase 2Active, not recruiting
- Sponsor
- German CLL Study Group
- Start
- Oct 2020
- Primary completion
- Feb 2027
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine, obinutuzumab, zanubrutinib, venetoclax in chronic lymphocytic leukemia (CLL), sponsored by German CLL Study Group. Started Oct 2020; status: active, not recruiting.
02
Drugs
bendamustineobinutuzumabzanubrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04515238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515238.